Steroidal 5α-Reductase and 17α-Hydroxylase/17,20-Lyase (CYP17) Inhibitors Useful in the Treatment of Prostatic Diseases

    May 2013 in “ The Journal of Steroid Biochemistry and Molecular Biology ”
    Jorge A. R. Salvador, Rui M. A. Pinto, Samuel Silvestre
    Image of study
    TLDR Certain drugs that block specific enzymes can help treat prostate diseases.
    The document from 2013 reviews the use of steroidal inhibitors targeting 5α-reductase and CYP17 enzymes in the treatment of prostatic diseases such as benign prostatic hyperplasia (BPH) and prostate cancer (PC). It discusses the clinical use of finasteride and dutasteride, which are 5α-reductase inhibitors, and their impact on reducing prostatic volume and improving urinary symptoms in BPH. The paper also covers the development of CYP17 inhibitors, including abiraterone acetate, which was FDA-approved for metastatic castration-resistant prostate cancer (mCRPC) treatment. The document highlights the challenges in designing these inhibitors, the importance of understanding enzyme structure for drug design, and the need for more studies to establish their role in BPH and PC prevention. It also mentions the potential association of 5α-reductase inhibitors with high-grade cancers and the importance of evaluating inhibitors using human enzymes. The document does not provide specific numbers of people involved in the studies, as it is a general review rather than a report on a specific clinical trial.
    Discuss this study in the Community →

    Research cited in this study

    17 / 17 results

    Related Community Posts Join

    6 / 125 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 10 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community Sugar and Hair loss connections

      in Research/Science  41 upvotes 1 month ago
      High sugar diets may worsen hair loss by increasing 5α-reductase activity and androgen levels, especially in women with PCOS. A low sugar diet might reduce scalp DHT levels, similar to finasteride, but genetics also significantly influence hair loss.

      community NW5 at 19. How many grafts do I need?

      in Transplants  138 upvotes 1 year ago
      A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.

    Related Research

    3 / 3 results